Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A review of criteria strictness in “Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials”
Motoki Amai, Masanori Nojima, Yoshikazu Yuki, et al.
Vaccine (2023) Vol. 41, Iss. 38, pp. 5622-5629
Open Access | Times Cited: 108

Showing 1-25 of 108 citing articles:

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Lisa A. Jackson, Evan J. Anderson, Nadine Rouphael, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 20, pp. 1920-1931
Open Access | Times Cited: 3229
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses
Kapil Bahl, Joe J. Senn, Olga Yuzhakov, et al.
Molecular Therapy (2017) Vol. 25, Iss. 6, pp. 1316-1327
Open Access | Times Cited: 589
Probiotic helminth administration in relapsing–remitting multiple sclerosis: a phase 1 study
J. O. Fleming, Alexander Isaak, JE Lee, et al.
Multiple Sclerosis Journal (2011) Vol. 17, Iss. 6, pp. 743-754
Open Access | Times Cited: 244
Tolerability, usability and acceptability of dissolving microneedle patch administration in human subjects
Jaya Arya, Sébastien Henry, Haripriya Kalluri, et al.
Biomaterials (2017) Vol. 128, pp. 1-7
Open Access | Times Cited: 197
Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial
Cassandra Aldrich, Isabel Leroux‐Roels, Katell Bidet Huang, et al.
Vaccine (2021) Vol. 39, Iss. 8, pp. 1310-1318
Open Access | Times Cited: 161
Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial
Martina Schneider, Marivic Narciso-Abraham, Sandra Hadl, et al.
The Lancet (2023) Vol. 401, Iss. 10394, pp. 2138-2147
Open Access | Times Cited: 117
Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial
Firdausi Qadri, Farhana Khanam, Xinxue Liu, et al.
The Lancet (2021) Vol. 398, Iss. 10301, pp. 675-684
Open Access | Times Cited: 112
A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus
Allison August, Husain Attarwala, Sunny Himansu, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2224-2233
Open Access | Times Cited: 111
CLSI-Derived Hematology and Biochemistry Reference Intervals for Healthy Adults in Eastern and Southern Africa
Etienne Karita, Nzeera Ketter, Matt A. Price, et al.
PLoS ONE (2009) Vol. 4, Iss. 2, pp. e4401-e4401
Open Access | Times Cited: 160
Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania
Zacchaeus Anywaine, Hilary Whitworth, Pontiano Kaleebu, et al.
The Journal of Infectious Diseases (2019) Vol. 220, Iss. 1, pp. 46-56
Open Access | Times Cited: 136
Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study
Mark S. Riddle, Robert W. Kaminski, Claudio Di Paolo, et al.
Clinical and Vaccine Immunology (2016) Vol. 23, Iss. 12, pp. 908-917
Open Access | Times Cited: 135
Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies
Gautam Goel, Tim King, A. James M. Daveson, et al.
˜The œLancet. Gastroenterology & hepatology (2017) Vol. 2, Iss. 7, pp. 479-493
Open Access | Times Cited: 130
Safety and Immunogenicity of rSh28GST Antigen in Humans: Phase 1 Randomized Clinical Study of a Vaccine Candidate against Urinary Schistosomiasis
Gilles Riveau, Dominique Deplanque, Franck Remoué, et al.
PLoS neglected tropical diseases (2012) Vol. 6, Iss. 7, pp. e1704-e1704
Open Access | Times Cited: 128
Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial
Mahamadou S. Sissoko, Sara A. Healy, Abdoulaye Katilé, et al.
The Lancet Infectious Diseases (2021) Vol. 22, Iss. 3, pp. 377-389
Open Access | Times Cited: 67
Adverse events following immunization of COVID‐19 (Covaxin) vaccine at a tertiary care center of India
Swayam Pragyan Parida, Dinesh Prasad Sahu, Arvind Kumar Singh, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 6, pp. 2453-2459
Open Access | Times Cited: 46
Spontaneous tumor regression following COVID-19 vaccination
Luana Guimarães de Sousa, Daniel J. McGrail, Kaiyi Li, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 3, pp. e004371-e004371
Open Access | Times Cited: 43
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial
Ngoc H. Tan, Daryl Geers, Roos S. G. Sablerolles, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 8, pp. 901-913
Open Access | Times Cited: 27
Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial
Joon Young Song, Won Suk Choi, Jung Yeon Heo, et al.
EClinicalMedicine (2023) Vol. 64, pp. 102140-102140
Open Access | Times Cited: 27
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial
Brittany L Ober Shepherd, Paul T Scott, Jack N Hutter, et al.
The Lancet Microbe (2024) Vol. 5, Iss. 6, pp. e581-e593
Closed Access | Times Cited: 13
The Oral, Live Attenuated Enterotoxigenic Escherichia coli Vaccine ACE527 Reduces the Incidence and Severity of Diarrhea in a Human Challenge Model of Diarrheal Disease
Michael J. Darsley, Subhra Chakraborty, Barbara DeNearing, et al.
Clinical and Vaccine Immunology (2012) Vol. 19, Iss. 12, pp. 1921-1931
Open Access | Times Cited: 102
Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: A Phase 1 dose-escalation study in healthy adults
James F. Cummings, Melanie Guerrero, James E. Moon, et al.
Vaccine (2013) Vol. 32, Iss. 19, pp. 2251-2259
Open Access | Times Cited: 94
Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naïve volunteers: effect of injection volume and dose on infectivity rates
Gloria P. Gómez-Pérez, Almudena Legarda, José Muñóz, et al.
Malaria Journal (2015) Vol. 14, Iss. 1
Open Access | Times Cited: 84
Safety and Immunogenicity of a Plant-Produced Recombinant Hemagglutinin-Based Influenza Vaccine (HAI-05) Derived from A/Indonesia/05/2005 (H5N1) Influenza Virus: A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study in Healthy Adults
Jessica A. Chichester, R. Mark Jones, Brian J. Green, et al.
Viruses (2012) Vol. 4, Iss. 11, pp. 3227-3244
Open Access | Times Cited: 75
Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma
Daniel Tusé, Nora Ku, Maurizio Bendandi, et al.
BioMed Research International (2015) Vol. 2015, pp. 1-15
Open Access | Times Cited: 68
Advancing Global Health through Development and Clinical Trials Partnerships: A Randomized, Placebo-Controlled, Double-Blind Assessment of Safety, Tolerability, and Immunogenicity of PfSPZ Vaccine for Malaria in Healthy Equatoguinean Men
Ally Olotu, Vicente Urbano, Ali Hamad, et al.
American Journal of Tropical Medicine and Hygiene (2017) Vol. 98, Iss. 1, pp. 308-318
Open Access | Times Cited: 68
Page 1 - Next Page

Scroll to top